Sun Pharma Eyes $10 Billion Organon Acquisition in US, Largest Ever for Indian Pharma

• Sun Pharma is reportedly preparing for a massive $10 billion acquisition of US-based Organon Pharma, potentially the largest by an Indian pharma company.
• The deal, possibly a slump sale, aims to significantly strengthen Sun Pharma's biosimilar portfolio and expand its presence in the US market.
• Organon Pharma, currently facing financial struggles with approximately $8 billion in debt and a market cap of $2 billion, specializes in women's health and specialty drugs.
• Despite Organon's poor financial health, its annual EBITDA run rate is $2 billion, with significant earnings from the US, EU, Canada, and Asia.
• Sun Pharma's shares on NSE are trading at ₹1676.80, showing a slight gain today but a decline over the past week, month, and year.

Why It Matters: Sun Pharma is planning a historic $10 billion acquisition of Organon to boost its biosimilar portfolio.